Aida Ormazabal

Aida Ormazabal

Auto-generated profile, based on publicly available information

Aida Ormazabal

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2018 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
CVClara Vilches
Clara Vilches
EBEmilia Boiadjieva-Knöpfel
Emilia Boiadjieva-Knöpfel
SBSusanna Bodoy
Susanna Bodoy
SCSimone Camargo
Simone Camargo
MHMiguel López de Heredia
Miguel López de Heredia
MPManuel Palacín
Manuel Palacín
Background Reabsorption of amino acids (AAs) across the renal proximal tubule is crucial for intracellular and whole organism AA homeostasis. Although the luminal transport step is well understood, with several diseases caused by dysregulation of this process, the basolateral transport step is not understood. In humans, only cationic aminoaciduria due to malfunction of the basolateral transporter y+LAT1/CD98hc (SLC7A7/SLC3A2), which mediates the export of cationic AAs, has been described. Thus, the physiologic roles of basolateral transporters of neutral AAs, such as the antiporter LAT2/CD98hc (SLC7A8/SLC3A2), a heterodimer that exports most neutral AAs, and the uniporter TAT1 (SLC16A10), which exports only aromatic AAs, remain unclear. Functional cooperation between TAT1 and LAT2/CD98hc has been suggested by in vitro studies but has not been evaluated in vivo. Methods To study the functional relationship of TAT1 and LAT2/CD98hc in vivo, we generated a double-knockout mouse model lacking TAT1 and LAT2, the catalytic subunit of LAT2/CD98hc (dKO LAT2-TAT1 mice). Results Compared with mice lacking only TAT1 or LAT2, dKO LAT2-TAT1 mice lost larger amounts of aromatic and other neutral AAs in their urine due to a tubular reabsorption defect. Notably, dKO mice also displayed decreased tubular reabsorption of cationic AAs and increased expression of y+LAT1/CD98hc. Conclusions The LAT2/CD98hc and TAT1 transporters functionally cooperate in vivo, and y+LAT1/CD98hc may compensate for the loss of LAT2/CD98hc and TAT1, functioning as a neutral AA exporter at the expense of some urinary loss of cationic AAs. Cooperative and compensatory mechanisms of AA transporters may explain the lack of basolateral neutral aminoacidurias in humans.

9 June 2010 in Movement Disorders
Verified
Journal Article
Open access
PDF file
RPRoser Pons
Roser Pons
Mercedes SerranoMercedes Serrano
Mercedes Serrano
AOAida Ormazabal
Aida Ormazabal
Claudio TomaClaudio Toma
Claudio Toma
AGAngels Garcia‐Cazorla
Angels Garcia‐Cazorla
RARafael Artuch
Rafael Artuch
We present the clinical, biochemical, and molecular findings of three Greek patients with tyrosine hydroxylase (TH) deficiency. All patients presented with a severe clinical phenotype characterized by prominent motor delay, infantile parkinsonism, oculogyric crises, and signs of autonomic dysfunction. Cerebrospinal fluid analysis disclosed reduced dopamine metabolites and normal pterins. Response to levodopa was favorable though not dramatic. All patients were homozygous for a previously reported mutation (p.L236P). SNP haplotype analysis was consistent with a common ancestral mutation, thus indicating a founder effect in Greek patients with TH deficiency. © 2010 Movement Disorder Society

16 June 2009 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ELEduardo López-Laso
Eduardo López-Laso
JOJuan José Ochoa-Sepúlveda
Juan José Ochoa-Sepúlveda
JOJuan José Ochoa-Amor
Juan José Ochoa-Amor
EBEnrique Bescansa-Heredero
Enrique Bescansa-Heredero
RCRafael Camino-León
Rafael Camino-León
KBKatrin Beyer
Katrin Beyer

2 May 2014 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
MCMercedes Casado
Mercedes Casado
LALaura Altimira
Laura Altimira
RMRaquel Montero
Raquel Montero
ECEsperanza Castejón
Esperanza Castejón
ANAndrés Nascimento
Andrés Nascimento
RARafael Artuch
Rafael Artuch

1 October 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
ADAlejandra Darling
Alejandra Darling
PIPilar Irún
Pilar Irún
PGPilar Giraldo
Pilar Giraldo
JAJudith Armstrong
Judith Armstrong
LMLaura Gort Mas
Laura Gort Mas
MOMar O'CAllaghan
Mar O'CAllaghan

7 March 2026 in Metabolomics
Verified
Journal Article
Open access
PDF file
ARArnau Gonzalez Rodriguez
Arnau Gonzalez Rodriguez
MUMireia Urpi-Sarda
Mireia Urpi-Sarda
BBBlanca Barrau-Martínez
Blanca Barrau-Martínez
FCFrancesc M. Campins-Machado
Francesc M. Campins-Machado
HBHadia Bakkali-Aissaoui
Hadia Bakkali-Aissaoui
RLRafael Llorach
Rafael Llorach
Background: Phenylketonuria (PKU) is a rare metabolic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase, leading to the accumulation of phenylalanine (Phe). Raised Phe levels can result in neurocognitive deficits, intellectual disabilities, and behavioral or psychiatric disorders. Aim of review: To conduct a systematic review of human studies on metabolites identified through metabolomics in individuals with PKU, compared to healthy controls, and to provide insights into their biological significance. Key scientific concepts of review: A total of 26 human studies analyzing metabolites in urine and blood met the inclusion criteria. In total, 544 metabolites that differed between patients with PKU and healthy controls were identified through different metabolomic techniques (LC-MS, GC-MS, NMR). Differences were primarily observed in blood samples, which accounted for 95% of the total metabolites, with only 5% detected in urine samples, reflecting the limited use of this body fluid in only five studies. We found 60% of blood metabolites upregulated in patients with PKU, including Phe, Phe-related metabolites, lipids, and other amino acids, while tryptophan and kynurenine, among others, were downregulated (40%). Additionally, 35 metabolites (6% of the total) exhibited inconsistent directions of change (both up- and downregulated), including amino acids, carnitine derivatives, and lipids. These findings may be attributed to clinical factors (dietary adherence, supplementation, and treatment) and methodological differences in blood-derived matrices. Consequently, the high heterogeneity across studies, biological matrices and analytical platforms represents limitations for establishing a unique metabolomic signature. Overall, these results emphasize the metabolic complexity of PKU and highlight the potential of metabolomics to advance disease monitoring and management.